✦ LIBER ✦

543 PREDICTION OF RESPONSE TO PEGINTERFERON FOR HBEAG-POSITIVE CHRONIC HEPATITIS B USING QUANTITATIVE SEROLOGY: HBEAG VERSUS HBSAG

✍ Scribed by M.J. Sonneveld; V. Rijckborst; B.E. Hansen; H.L. Janssen

Book ID: 117380755
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 72 KB
Volume: 56
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(12)60556-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Response-guided Peginterferon Therapy fo

Response-guided Peginterferon Therapy for HBeAg-positive and HBeAg-negative Chronic Hepatitis B using Hepatitis B Surface Antigen Levels: A Review

✍ Sonneveld, Milan J.; Brouwer, Willem P.; Janssen, Harry L. A. 📂 Article 📅 2014 🏛 Current Science Inc. 🌐 English ⚖ 233 KB

Polymorphisms Near IL28B and Serologic R

Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B

✍ Milan J. Sonneveld; Vincent W.–S. Wong; Andrea M. Woltman; Grace L.H. Wong; Yilm 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 938 KB

Use of on-Treatment HBsAg Level and HBeA

Use of on-Treatment HBsAg Level and HBeAg Index Can Early Predict Sustained Virological Response in Chronic Hepatitis B, HBeAg Positive Patients Treated With Peginterferon ALPHA-2A

✍ Phisalprapa, Pochamana ;Charatcharoenwitthaya, Phunchai ;Chainuvati, Siwaporn P. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 570 KB

917 ON-TREATMENT MONITORING OF HBsAg LEV

917 ON-TREATMENT MONITORING OF HBsAg LEVELS TO PREDICT RESPONSE TO PEGINTERFERON ALFA-2A IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B

✍ G.K.K. Lau; P. Marcellin; M. Brunetto; T. Piratvisuth; H.-P. Kapprell; D. Messin 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Early on-treatment prediction of respons

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels

✍ Vincent Rijckborst; Bettina E. Hansen; Yilmaz Cakaloglu; Peter Ferenci; Fehmi Ta 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB 👁 2 views

Ferenci is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. Dr. Janssen is a consultant for and received grants from Roche, Bristol-Myers Squibb, Schering-Plough, Novartis, and Gilead. Dr. Flisiak received grants from Roche.

Pretreatment HBeAg level and an early de

Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg-positive chronic hepatitis B

✍ J. H. Kwon; J. W. Jang; S. Lee; J. Lee; K. W. Chung; Y. S. Lee; J. Y. Choi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB